Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma.

Trial Profile

Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Mar 2018

At a glance

  • Drugs Sorafenib (Primary) ; Yttrium-90 (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SIRveNIB
  • Most Recent Events

    • 02 Mar 2018 Primary endpoint has not been met. (Overall Survival) as per results published in the Journal of Clinical Oncology
    • 02 Mar 2018 Results published in the Journal of Clinical Oncology
    • 24 Jul 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top